Rockville

THE DIOCESE OF ROCKVILLE CENTRE FILES PLAN OF REORGANIZATION

Retrieved on: 
Friday, January 27, 2023
Housing, Roman Catholic Diocese of Rockville Centre, Plan, Education, Director of communications, Title 11 of the United States Code, Food security, Bankruptcy, Communication, Rockville, Survivor, Rockville Centre, New York, Substance abuse, Insurance, Party, Committee, History, Mental health, Disclosure, Life insurance, Diocese

ROCKVILLE CENTRE, N.Y., Jan. 27, 2023 /PRNewswire/ -- The Diocese of Rockville Centre ( www.drvc.org ) filed its Plan and Disclosure Statement today, offering a substantial proposal for settling with survivors.

Key Points: 
  • ROCKVILLE CENTRE, N.Y., Jan. 27, 2023 /PRNewswire/ -- The Diocese of Rockville Centre ( www.drvc.org ) filed its Plan and Disclosure Statement today, offering a substantial proposal for settling with survivors.
  • The Diocese believes the Plan is the best means to efficiently and effectively pave the way for compensating survivors and emerging from bankruptcy.
  • To demonstrate its commitment to move forward, the Diocese has proposed a plan that it hopes provides a framework for a timely resolution of this bankruptcy case for survivors, the Diocese, and its parishes.
  • Under the Diocese's Plan the estimated total contribution from the Diocese, Parishes, its Co-Insured Parties, and other ministry members has a value between $185 million and $200 million.

On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group

Retrieved on: 
Wednesday, June 1, 2022
Azur, Managed services, ODP, Biotechnology, Rockville, World Economic Forum, Print on demand, Documentation, API, Environmental monitoring, Solution, Equipment, Technology, COVID-19, Compliance, State, Commission, Scientific American, CGMP, Pharmacy, Fine chemical, Risk management, Pharmaceutical industry

ROCKVILLE, Md., June 1, 2022 /PRNewswire/ -- On Demand Pharmaceuticals, Inc. (ODP), an innovative technology company transforming the way medicines are made, announced today that it has signed a Preferred Supplier agreement with Azzur Group through 2024.

Key Points: 
  • ROCKVILLE, Md., June 1, 2022 /PRNewswire/ -- On Demand Pharmaceuticals, Inc. (ODP), an innovative technology company transforming the way medicines are made, announced today that it has signed a Preferred Supplier agreement with Azzur Group through 2024.
  • The transformation of ODP's Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020.
  • From Discovery to Delivery, Azzur Group provides the life science community full life-cycle solutions for all their GxP needs.
  • From Azzur Cleanrooms on Demand facilities, to our labs, training centers, and consulting offices across the nation, Azzur Group helps organizations start, scale, and sustain their growing enterprises.

108 More Professionals Earn Regulatory Affairs Certification (RAC)

Retrieved on: 
Thursday, December 9, 2021
RAPS, RAC, GLOBE, Knowledge, Technology, Uncertainty, Medicine

Rockville, MD, USA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professionals Society (RAPS) today announced that 108 professionals passed the Regulatory Affairs Certification (RAC) exams in the summer exam window, which occurred in July and August 2021.

Key Points: 
  • Rockville, MD, USA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professionals Society (RAPS) today announced that 108 professionals passed the Regulatory Affairs Certification (RAC) exams in the summer exam window, which occurred in July and August 2021.
  • Passing the exam confers the RAC-Drugs and RAC-Devices credentials, the leading credentials for regulatory professionals in the healthcare product sector.
  • There are currently more than 5,000 professionals around the world who hold the RAC credentials.
  • RAC-credentialed professionals are among the current and rising leaders in the regulatory profession.

SOCIAL SECURITY ADMINISTRATION AND ABT RELEASE VOLUME ON LESSONS FROM 30 YEARS OF DEMONSTRATION PROJECTS

Retrieved on: 
Thursday, December 9, 2021

Rockville, Md., Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Social Security Administration (SSA) and Abt Associates have released a book, Lessons from SSA Demonstrations for Disability Policy and Future Research , that summarizes more than 30 years of demonstration projects, which tested new policies.

Key Points: 
  • Rockville, Md., Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Social Security Administration (SSA) and Abt Associates have released a book, Lessons from SSA Demonstrations for Disability Policy and Future Research , that summarizes more than 30 years of demonstration projects, which tested new policies.
  • The demonstrations aimed at improving the biggest federal disability programs, Social Security Disability Insurance (SSDI) and Supplemental Security Income (SSI) and helping the people who rely on them.
  • The volume is based on a State of the Science meeting that SSA, Abt, and its partner, the Hatcher Group, organized in spring 2021 to review the key lessons from SSAs demonstrations.
  • Recordings of the meeting can be found on Abts website and additional information is on SSAs website .

OpGen Announces Results of Special Meeting of Stockholders

Retrieved on: 
Wednesday, December 8, 2021
Cyprus Securities and Exchange Commission, Company, GLOBE, Precision medicine, Securities Act of 1933, Technology, NGS, Growth, Security (finance), Informatics, Private Securities Litigation Reform Act, Nadine Opgen-Rhein, Securities Exchange Act of 1934, Charter, Shareholder, COVID-19, Adoption, Goal, Infection, Nasdaq, Solution, Hospital

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen or the Company), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that stockholders have approved the two proposals voted on at the Companys Special Meeting of Stockholders held on December 8, 2021.

Key Points: 
  • ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen or the Company), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that stockholders have approved the two proposals voted on at the Companys Special Meeting of Stockholders held on December 8, 2021.
  • On proposal one, approximately 99.3% of the outstanding voting power of the Companys capital stock voted in favor of the proposal.
  • OpGens Chief Executive Officer, Oliver Schacht, commented, "We are very pleased that our stockholders strongly supported and voted to approve of these important matters.
  • This press release includes statements regarding the results of OpGens Special Meeting of Stockholders.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Central nervous system, Apomorphine, NDA, ADHD, Company, Torticollis, GLOBE, OFF, Refusal, Letter, Prescription, Growth, Security (finance), Safety, Private Securities Litigation Reform Act, Food, Patient, CEO, Securities Exchange Act of 1934, New Drug Application, Epilepsy, Migraine, Depression, CNS, Central nervous system disease, Adult, FDA, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, Section 13, Risk, Dyskinesia, Government, RTF, Pharmaceutical industry

The FDA provided additional clarity related to the contents of the November 2020 RTF letter and the requirements for resubmission during a Type A meeting with Supernus in March 2021.

Key Points: 
  • The FDA provided additional clarity related to the contents of the November 2020 RTF letter and the requirements for resubmission during a Type A meeting with Supernus in March 2021.
  • SPN-830 is an important product candidate which, if approved by the FDA, represents a novel approach for PD patients, said Jack Khattar, President and CEO of Supernus Pharmaceuticals.
  • We believe the continuous subcutaneous infusion of apomorphine for the treatment of motor fluctuations (OFF episodes) can be an attractive alternative for patients who are seeking less invasive options.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

CloudBolt 2022 Predictions: The New Cloud Order Accelerates, Requires Evolution to Cloud Governance

Retrieved on: 
Tuesday, December 7, 2021
Shift, Cloud, AWS, Environment, Awareness, GCP, GLOBE, Automation, Culture, Digital transformation, Efficiency, Google, Organization, Software and Information Industry Association, Azure, Policy, Time, CloudBolt, Solution, Insight Partners, Acquisition, Headache, Budget, Deloitte, Video game console, Asset management, Risk management

NORTH BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enterprise hybrid cloud management leader CloudBolt Software today released its predictions for cloud management in 2022 and beyond.

Key Points: 
  • NORTH BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enterprise hybrid cloud management leader CloudBolt Software today released its predictions for cloud management in 2022 and beyond.
  • But as cloud architectures grow more complex and more tools and platforms are added, cloud management can easily become overwhelming and fall behind.
  • Visibility, interoperability, sustainability, cost optimization and simplicity will be crucial in ensuring cloud management stays ahead of evolving cloud challenges.
  • In addition, CloudBolt is a 2020 CODiE award winner for best cloud management and featured in Gartners Magic Quadrant for Cloud Management Platforms.

Avalo Appoints Two New Independent Directors to Its Board

Retrieved on: 
Monday, December 6, 2021
University, Probability, Company, Lists of diseases, GSK, R, School, Master of Science, GLOBE, Haas, Board of directors, Board, University of California, University of Pennsylvania, Drug development, Private Securities Litigation Reform Act, Publication, Medical physics, Horizon Therapeutics, Faculty, Actavis, GlaxoSmithKline, American College, FACP, Smith College, Medical school, Duke, Forward-looking statement, MBA, Mergers and acquisitions, AOA, Takeda, AstraZeneca, Therapy, American College of Physicians, Rotman School of Management, Bachelor of Science, Stanford University Medical Center, Patient, Mergers & Acquisitions, Biomarker, Industry, Duke University School of Medicine, Stanford University, SEC, COVID-19, Nasdaq, Management, Pharmaceutical industry

These two new independent directors are replacing Dr. Suzanne Bruhn and Philip Gutry.

Key Points: 
  • These two new independent directors are replacing Dr. Suzanne Bruhn and Philip Gutry.
  • We are pleased to welcome both Dr. Almenoff and Mr. Chan to our Board.
  • I thank Sue and Phil for their service on the board and valuable contributions.
  • Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2 billion.

Disability-Led Nonprofit RespectAbility Receives $1 Million Grant From the Conrad N. Hilton Foundation

Retrieved on: 
Thursday, December 2, 2021
Conrad N. Hilton Foundation, Disability, Conrad, Mental health, Foundation, CEO, Private sector, News, Week, Bias, Education, Solution, Entrepreneurship, Chronic pain, NEWS, Person, ADHD, Stock, GLOBE, Atlante (private equity fund), Board of directors, Organization, Board, AND, RespectAbility, Government, Mizrahi Jews, Employment, Eagle Scout (Boy Scouts of America), The Cantos, Management, Cryptocurrency

The funds will be leveraged through an existing 1-1 matching campaign to enable RespectAbility to achieve the paradigm-shifting goals of its new strategic plan .

Key Points: 
  • The funds will be leveraged through an existing 1-1 matching campaign to enable RespectAbility to achieve the paradigm-shifting goals of its new strategic plan .
  • "In 2020, the Hilton Foundation established the Equity Fund to combat bias and injustice across multiple dimensions, including for people with disabilities," said Peter Laugharn, president, and CEO of the Conrad N. Hilton Foundation.
  • The Foundation is proud to support RespectAbility, a disability-led organization doing transformative, comprehensive work to fight stigmas for people living with disabilities."
  • RespectAbility's founder and CEO Jennifer Laszlo Mizrahi said, "We are deeply grateful to the Conrad N. Hilton Foundation for this significant game-changing donation.

RAPS Releases Updated Regulatory Competency Framework

Retrieved on: 
Wednesday, December 1, 2021
Government, Industry, Publication, Ethics, Leadership, RAC, Education, RAPS, Research, GLOBE, Organization, Healthcare, Risk management

Rockville, MD, USA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professionals Society (RAPS) today announced the release of its updated Regulatory Competency Framework , describing the essential elements of what is required of regulatory professionals at four key career and professional levels.

Key Points: 
  • Rockville, MD, USA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professionals Society (RAPS) today announced the release of its updated Regulatory Competency Framework , describing the essential elements of what is required of regulatory professionals at four key career and professional levels.
  • The framework breaks down regulatory competencies into clear, easy-to-understand statements, categorized into seven knowledge domains: leadership, ethics, business acumen, scientific and health concepts, product development and registration, regulatory framework and strategy, and postapproval/postmarket.
  • The framework is the result of years of ongoing research and development with the guidance of RAPS members and volunteer experts.
  • The Regulatory Competency Framework is available for free and can be downloaded at www.RAPS.org/Competency .